IP Library Patent Application 17822175
Patent Application
App. No. 17/822,175

LACTOFERRIN COMPOSITIONS AND METHODS FOR MODULATION OF T CELL SUBTYPES AND TREATMENT OF AUTOIMMUNE DISEASES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/822,175
Abstract

Methods of inducing a regulatory T cell (Treg) phenotype and skewing naïve T cells toward a pro-regulatory phenotype are disclosed.

Claims (17)

1 . A method for inducing a regulatory T cell (Treg) phenotype, said method comprising contacting an initial population of T cells with lactoferrin, wherein said T cells exhibit a Treg phenotype after said contacting.

2 . The method of claim 1 , said method comprising activating T cells in the presence of said lactoferrin.

3 . The method of claim 1 , said method comprising stimulating T cells in the presence of said lactoferrin.

4 . The method of claim 1 , said method comprising culturing said T cells in the presence of said lactoferrin.

5 . The method of claim 1 , wherein said initial population of T cells comprises CD4+ and/or CD8+ T cells.

6 . The method of claim 1 , wherein said initial population of T cells is induced towards a Treg phenotype and away from a proinflammatory Th1/17 phenotype.

7 . The method of claim 1 , wherein said Treg phenotype comprises FoxP3 expression.

8 . The method of claim 1 , wherein said Treg phenotype is increased in said population of cells, and wherein any conversion of said T cells into Th1 cells is decreased as compared to a control.

9 . The method of claim 1 , wherein a Th1/Th17 T cell phenotype is inhibited in said population of T cells.

10 . The method of claim 1 , wherein said method comprises upregulating genes (Fosl1, Foxp3, Ikzf2, Irf1, Irf4, and/or Tgif) involved in Treg generation, and concomitantly downregulating genes (Il-17a, Il17re, and/or Rora) involved in regulating Th17 phenotype.

11 . The method of claim 1 , further comprising expanding said population of T cells to increase said Treg cells.

12 . The method of claim 1 , wherein said lactoferrin is native lactoferrin isolated and purified from a mammal or mammalian secretion.

13 . The method of claim 1 , wherein said lactoferrin is mammalian lactoferrin recombinantly expressed in a host system.

14 . The method of claim 13 , wherein said host system is a plant, microorganism, yeast, fungi, insect system, or animal cell system.

15 . The method of claim 1 , wherein said contacting is carried out in an in vitro culture system.

16 . The method of claim 1 , wherein said population of T cells has an increase in Treg numbers.

17 . The method of claim 1 , wherein said Tregs express increased levels of IL-10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: MACMANUS, CHRISTOPHER
To: VENTRIA BIOSCIENCE INC.
Reel/Frame 060963/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: COLLINS, COLM; DE ZOETEN, EDWIN
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 060963/0276 →